Vivos Therapeutics, Inc. Increase (Decrease) in Deferred Compensation
Vivos Therapeutics, Inc. (VVOS) reported Increase (Decrease) in Deferred Compensation of $548.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredCompensation · last filed 2022-03-31
- Vivos Therapeutics, Inc. increase (decrease) in deferred compensation for the quarter ending 2021-12-31 was $351.96K.
- Vivos Therapeutics, Inc. increase (decrease) in deferred compensation for the quarter ending 2021-09-30 was $1.60K, a 97.98% decline year-over-year.
- Vivos Therapeutics, Inc. increase (decrease) in deferred compensation for the quarter ending 2021-06-30 was $146.32K, a 664.43% increase year-over-year.
- Vivos Therapeutics, Inc. increase (decrease) in deferred compensation for the quarter ending 2021-03-31 was $48.11K, a 3.50% decline year-over-year.
- Vivos Therapeutics, Inc. increase (decrease) in deferred compensation for fiscal 2021 was $548.00K, a 585.00% increase from fiscal 2020.
- Vivos Therapeutics, Inc. increase (decrease) in deferred compensation for fiscal 2020 was $80.00K, a 34.08% increase from fiscal 2019.
- Vivos Therapeutics, Inc. increase (decrease) in deferred compensation for fiscal 2019 was $59.67K.
| Period end | Increase (Decrease) in Deferred Compensation 3 month | Increase (Decrease) in Deferred Compensation 6 month | Increase (Decrease) in Deferred Compensation 9 month | Increase (Decrease) in Deferred Compensation 12 month | Increase (Decrease) in Deferred Compensation 12 month as first filed |
|---|---|---|---|---|---|
| 2021-12-31 | $351.96K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $353.57K derived: sum of 2 quarters · filed 2022-03-31 | $499.89K derived: sum of 3 quarters · filed 2022-03-31 | $548.00K 10-K · filed 2022-03-31 | |
| 2021-09-30 | $1.60K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $147.93K derived: sum of 2 quarters · filed 2021-11-15 | $196.03K 10-Q · filed 2021-11-15 | $127.65K derived: sum of 4 quarters · filed 2022-03-31 | |
| 2021-06-30 | $146.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $194.43K 10-Q · filed 2021-08-12 | $126.04K derived: sum of 3 quarters · filed 2022-03-31 | $205.43K derived: sum of 4 quarters · filed 2022-03-31 | |
| 2021-03-31 | $48.11K 10-Q · filed 2021-05-17 | -$20.28K derived: sum of 2 quarters · filed 2022-03-31 | $59.11K derived: sum of 3 quarters · filed 2022-03-31 | $78.25K derived: sum of 4 quarters · filed 2022-03-31 | |
| 2020-12-31 | -$68.39K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $11.00K derived: sum of 2 quarters · filed 2022-03-31 | $30.14K derived: sum of 3 quarters · filed 2022-03-31 | $80.00K 10-K · filed 2022-03-31 | $79.72K 10-K · filed 2021-03-25 |
| 2020-09-30 | $79.39K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $98.53K derived: sum of 2 quarters · filed 2021-11-15 | $148.39K 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $19.14K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $69.00K 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $49.85K 10-Q · filed 2021-05-17 | ||||
| 2019-12-31 | $59.67K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |